arrow
M

Michele Basso

fondazione policlinico universitario agostino gemelli irccs
H指数:19
被引数:1,181

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Interobserver Agreement and Radiological–Pathological Concordance of CT Staging in localized Colon Cancer

不同观察者间对局部结肠癌CT分期的观察者一致性及影像学-病理学一致性

2026-09-010
OAAI
Real-world outcomes of Adjuvant De Gramont versus Xelox chemotherapy in reSected gasTric cancER: a propensity score-matched analysis (ASTER study)

ASTEROID研究:辅助De Gramont方案与Xelox化疗在切除胃癌中的真实世界疗效比较:一项倾向性评分匹配分析

2025-07-260
OAAI
The Impact of a Multidisciplinary Tumor Board (MDTB) in the Management of Colorectal Cancer (CRC)

多学科肿瘤委员会(MDTB)在结直肠癌(CRC)管理中的影响

2025-01-100
OA
Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort

阿柏西普为基础和贝伐珠单抗为基础的二线方案在转移性结直肠癌患者中的应用:一项多中心队列研究的倾向性评分加权分析

2025-01-020
OAAI
Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis
2024-04-131
OAAI
Hug sign in intraprocedural cone-beam-CT to predict short-term response to combined treatment of hepatocellular carcinoma

术中锥形束CT中拥抱标志预测肝细胞癌联合治疗的短期反应

2024-03-210
OAAI
Aflibercept-based and bevacizumab-based second-line regimens in patients with RAS mutant metastatic colorectal cancer: Propensity score weighted-analysis from a multicenter cohort
2023-06-010
OA
Aflibercept-based and bevacizumab-based second-line regimens in patients with RAS/BRAF wild type metastatic colorectal cancer: Propensity score weighted-analysis from a multicenter cohort
2023-06-010
OAAI
Influence of age on disease control rate of patients treated with regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A multicenter retrospective real-world study
2023-06-010
OA
Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report

恩可非尼和西妥昔单抗转化治疗化疗难治性BRAF V600E-Mutated肝限制性结直肠癌转移: 第一例报告

2021-12-010
PRE